Angie You bought $263k of ORIC
director at Oric Pharmaceuticals, Inc.. 28,000 shares at an average of $9.39, traded Jun 20, 2025, filed Jun 23, 2025.
Score components
- +15RoleDirector
- +13Trade size$263k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +4Price context26% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +18.0%, 3m +8.2%, 6m -16.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-018014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | POpen-market purchase Common Stock | +26,597 | $9.39 | $250k | 26,597 | Jun 23, 2025 |
| Jun 23, 2025 | POpen-market purchase Common Stock | +1,403 | $9.43 | $13k | 28,000 | Jun 23, 2025 |
Related signals
Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $87k 6,700 shares | -16% | |
| 12Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $181k 13,400 shares | -16% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $8,103 600 shares | -1% | |
| 32Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $1.1M 77,000 shares | -52% | |
| 1Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $157k 13,100 shares | -29% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $3,600 300 shares | -0% | |
| 18Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $703k 52,000 shares | -43% | |
| 9Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $80k 6,700 shares | -15% | |
| 39Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $302k 33,374 shares | -5% | |
| 30Weak | Oric Pharmaceuticals, Inc. | Pratik S Multani Chief Medical Officer | $97k 10,720 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.